Download PDF
Drug Res (Stuttg) 2017; 67(09): 527-533
DOI: 10.1055/s-0043-109001
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of Bone Mineral Density in Children with Type I Diabetes Mellitus and Relationship to Serum Levels of Osteopontin

Forough Saki   *
1   Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Abdolkarim Sheikhi   *
2   Department of Immunology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran
,
Gholam Hosein Ranjbar Omrani
1   Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Hamid Karimi
1   Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Mohammad Hossein Dabbaghmanesh
1   Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Seyed Nouraddin Mousavinasab
3   Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran
› Author Affiliations
Further Information

Publication History

received 27 November 2016

accepted 11 April 2017

Publication Date:
12 May 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background

Type I diabetes mellitus (T1DM) patients are at risk of osteoporosis and fracture due to the osteoblast and osteoclast malfunction. Osteopontin (OPN) as the major non-collagenous bone matrix protein is produced by osteoblasts and osteoclasts and involve in bone resorption, formation and remodeling. To evaluate the serum levels of OPN, bone mineral density (BMD) and correlation in patients with T1DM this study was designed.

Methods

In this case-control study, 87 children with T1DM and 87 age/sex-matched healthy subjects were enrolled. Blood samples were tested for OPN levels by ELISA. Dual energy X-ray absorptiometry was used to measure BMD.

Results

The mean levels of BMD in patients was significantly lower than control group (p<0.0001). There was no significant difference between patients and healthy subjects regarding the levels of OPN. However, in patients with high levels of OPN (mean+1.5 standard deviation) the BMD was significantly lower than other patients (p<0.0001). Totally there was a negative correlation between serum levels of OPN and BMD in patients with T1DM (p<0.016).

Conclusion

These results indicated that the BMD in T1DM is less than healthy children and elevated level of OPN in patients could be associated with low BMD. A linear negative correlation between serum OPN and total BMD of T1DM patients compared to control group was noticed in this study indicating that the amount of serum OPN could be effective on BMD and a good predicting factor for osteoporosis in patients.

Key words

osteopontin - bone mineral density - type I diabetes mellitus - osteoporosis

* The first and second authors are of equal rights.


 

  • References

  • 1 Schranzand DB, Lernmark A. Immunology in diabetes: An update. Diabetes Metabolism Reviews-Clinical and Scientific Advances in Diabetes Research 1998; 14: 3-30
    PubMedGoogle Scholar
  • 2 Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029
    CrossrefPubMedGoogle Scholar
  • 3 Davis IC, Randell J, Davis SN. Immunotherapies currently in development for the treatment of type 1 diabetes. Expert opinion on investigational drugs 2015; 24: 1331-1341
    CrossrefPubMedGoogle Scholar
  • 4 Eizirikand DL, Mandrup-Poulsen T. A choice of death–the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133
    CrossrefPubMedGoogle Scholar
  • 5 Hamilton E, Rakic V, Davis W. et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabetic Medicine 2009; 26: 45-52
    CrossrefPubMedGoogle Scholar
  • 6 Mastrandrea LD, Wactawski-Wende J, Donahue RP. et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008; 31: 1729-1735
    CrossrefPubMedGoogle Scholar
  • 7 Saha M, Sievänen H, Salo M. et al. Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. Osteoporosis International 2009; 20: 1401-1406
    CrossrefPubMedGoogle Scholar
  • 8 Lumachi F, Camozzi V, Tombolan V. et al. Bone mineral density, osteocalcin, and bone-specific alkaline phosphatase in patients with insulin-dependent diabetes mellitus. Annals of the New York Academy of Sciences 2009; 1173: E64-E67
    CrossrefPubMedGoogle Scholar
  • 9 Napoli N, Chandran M, Pierroz DD et al. Mechanisms of diabetes mellitus-induced bone fragility. Nature Reviews Endocrinology 2016
    PubMed
  • 10 Silva MJ, Brodt MD, Lynch MA. et al. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. Journal of Bone and Mineral Research 2009; 24: 1618-1627
    CrossrefPubMedGoogle Scholar
  • 11 Sheikhi A, Rangchi M, Ghaaed V. et al. Effects of garlic (Allium Sativum) extract on the expression of receptor for advanced glycation end products and pro-inflammatory cytokines secretion in peripheral blood mononuclear cells from patients with type 2 diabetes mellitus. Archives of Medical Laboratory Sciences 2015; 1: 1-10
    PubMedGoogle Scholar
  • 12 Sheikhi A, Tayade C, Paffaro V. et al. Are natural killer cells distributed in relationship to nerve fibers in the pregnant mouse uterus?. Pakistan journal of biological sciences: PJBS 2007; 10: 2885-2889
    CrossrefPubMedGoogle Scholar
  • 13 Tomasek JJ, Meyers SW, Basinger JB. et al. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life sciences 1994; 55: 855-861
    CrossrefPubMedGoogle Scholar
  • 14 Saito M, Fujii K, Mori Y. et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporosis international 2006; 17: 1514-1523
    CrossrefPubMedGoogle Scholar
  • 15 Chen J, Singh K, Mukherjee BB. et al. Developmental expression of osteopontin (OPN) mRNA in rat tissues: Evidence for a role for OPN in bone formation and resorption. Matrix 1993; 13: 113-123
    CrossrefPubMedGoogle Scholar
  • 16 Giachelli CM, Schwartz SM, Liaw L. Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends in cardiovascular medicine 1995; 5: 88-95
    CrossrefPubMedGoogle Scholar
  • 17 Rittlingand SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Nephron Experimental Nephrology. 1999; 7: 103-113
    CrossrefPubMedGoogle Scholar
  • 18 Weberand GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokine & Growth Factor Reviews 1996; 7: 241-248
    CrossrefPubMedGoogle Scholar
  • 19 Giachelli CM, Lund SA, Scatena M. The role of osteopontin in inflammatory processes. Journal of Cell Communication and Signaling 2009; 3: 311-322
    CrossrefPubMedGoogle Scholar
  • 20 McKee M, Zalzal S, Nanci A. Extracellular matrix in tooth cementum and mantle dentin: Localization of osteopontin and other noncollagenous proteins, plasma proteins, and glycoconjugates by electron microscopy. The Anatomical Record 1996; 245: 293-312
    CrossrefPubMedGoogle Scholar
  • 21 Sato M, Morii E, Komori T. et al. Transcriptional regulation of osteopontin gene in vivo by PEBP2aA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 1998; 17: 1517-1526
    CrossrefPubMedGoogle Scholar
  • 22 Hofbauer L. From Bone cell biology to novel therapies of osteoporosis. Drug Research 2015; 65: S14-S15
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Ihara H, Denhardt DT, Furuya K. et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. Journal of Biological Chemistry 2001; 276: 13065-13071
    CrossrefPubMedGoogle Scholar
  • 24 Yoshitake H, Rittling SR, Denhardt DT. et al. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proceedings of the National Academy of Sciences 1999; 96: 8156-8160
    CrossrefPubMedGoogle Scholar
  • 25 Franzén A, Hultenby K, Reinholt FP. et al. Altered osteoclast development and function in osteopontin deficient mice. Journal of Orthopaedic Research 2008; 26: 721-728
    CrossrefPubMedGoogle Scholar
  • 26 Boskey A, Maresca M, Ullrich W. et al. Osteopontin-hydroxyapatite interactions in vitro: Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone and mineral 1993; 22: 147-159
    CrossrefPubMedGoogle Scholar
  • 27 Steinman L. A rush to judgment on Th17. Journal of Experimental Medicine 2008; 205: 1517-1522
    CrossrefPubMedGoogle Scholar
  • 28 Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury 1. Annual Review of Pharmacology and Toxicology 2001; 41: 723-749
    PubMedGoogle Scholar
  • 29 Giachelliand CM, Steitz S. Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biology 2000; 19: 615-622
    CrossrefPubMedGoogle Scholar
  • 30 Aspord C, Rome S, Thivolet C. Early events in islets and pancreatic lymph nodes in autoimmune diabetes. Journal of Autoimmunity 2004; 23: 27-35
    CrossrefPubMedGoogle Scholar
  • 31 Fierabracci A, Biro PA, Yiangou Y. et al. Osteopontin is an autoantigen of the somatostatin cells in human islets: Identification by screening random peptide libraries with sera of patients with insulin-dependent diabetes mellitus. Vaccine 1999; 18: 342-354
    CrossrefPubMedGoogle Scholar
  • 32 Chang I-C, Chiang T-I, Yeh K-T. et al. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporosis International 2010; 21: 1401-1409
    CrossrefPubMedGoogle Scholar
  • 33 A.D. Association. Standards of medical care in diabetes—2013. Diabetes care 36: S11 2013;
    CrossrefPubMedGoogle Scholar
  • 34 Kanis JA, Borgstrom F, De Laet C. et al. Assessment of fracture risk. Osteoporosis International 2005; 16: 581-589
    CrossrefPubMedGoogle Scholar
  • 35 Moerman EJ, Teng K, Lipschitz DA. et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell 2004; 3: 379-389
    CrossrefPubMedGoogle Scholar
  • 36 Lecka-Czernik B, Gubrij I, Moerman EJ. et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. Journal of Cellular Biochemistry 1999; 74: 357-371
    CrossrefPubMedGoogle Scholar
  • 37 Botolinand S, McCabe LR. Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss. Journal of cellular physiology 2006; 209: 967-976
    CrossrefPubMedGoogle Scholar
  • 38 Gopalakrishnan V, Vignesh R, Arunakaran J. et al. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochemistry and cell biology 2006; 84: 93-101
    CrossrefPubMedGoogle Scholar
  • 39 Lu H, Kraut D, Gerstenfeld LC. et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003; 144: 346-352
    CrossrefPubMedGoogle Scholar
  • 40 Lechleitner M, Koch T, Herold M. et al. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. Journal of Internal Medicine 2000; 248: 67-76
    CrossrefPubMedGoogle Scholar
  • 41 Coe LM, Irwin R, Lippner D. et al. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. Journal of Cellular Physiology 2011; 226: 477-483
    CrossrefPubMedGoogle Scholar
  • 42 Sharifi F, Sheikhi A, Behdad M. et al. Effect of garlic on serum adiponectin and interleukin levels in women with metabolic syndrome. Int J Endocrinol Metab 2010; 8: 68-73
    PubMedGoogle Scholar
  • 43 Sheikhi A, Nazarian M, Nasab NM. et al. In-vitro effects of Mycobacterium bovis BCG-lysate and its derived heat shock proteins on cytokines secretion by blood mononuclear cells of rheumatoid arthritis patients in comparison with healthy controls. International Immunopharmacology 2008; 8: 887-892
    CrossrefPubMedGoogle Scholar
  • 44 Fraser J, Helfrich M, Wallace H. et al. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 1996; 19: 223-226
    CrossrefPubMedGoogle Scholar
  • 45 Gong Q, Chipitsyna G, Gray CF. et al. Expression and regulation of osteopontin in type 1 diabetes. Islets 2009; 1: 34-41
    CrossrefPubMedGoogle Scholar
  • 46 Oldberg A, Franzén A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proceedings of the National Academy of Sciences 1986; 83: 8819-8823
    CrossrefPubMedGoogle Scholar
  • 47 Chellaiah MA, Kizer N, Biswas R. et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Molecular Biology of the Cell 2003; 14: 173-189
    CrossrefPubMedGoogle Scholar
  • 48 Dang Z, Van Bezooijen R, Karperien M. et al. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. Journal of Bone and Mineral Research 2002; 17: 394-405
    CrossrefPubMedGoogle Scholar
  • 49 Okazaki R, Inoue D, Shibata M. et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) α or β. Endocrinology 2002; 143: 2349-2356
    CrossrefPubMedGoogle Scholar
  • 50 Takemoto M, Yokote K, Nishimura M. et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20: 624-628
    CrossrefPubMedGoogle Scholar
  • 51 Asaumi S, Takemoto M, Yokote K. et al. Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. Journal of Diabetes and its Complications 2003; 17: 34-38
    CrossrefPubMedGoogle Scholar
  • 52 Fischer JW, Tschöpe C, Reinecke A. et al. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 1998; 47: 1512-1518
    CrossrefPubMedGoogle Scholar
  • 53 Karamizadeh Z, Sarvestani EK, Saki F. et al. Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in Type 1 diabetes mellitus. Journal of Endocrinological Investigation 2013; 36: 1090-1093
    PubMedGoogle Scholar
  • 54 Ren X, Shao H, Wei Q. et al. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. Journal of International Medical Research 2009; 37: 847-854
    CrossrefPubMedGoogle Scholar
  • 55 Lenga Y, Koh A, Perera AS. et al. Osteopontin expression is required for myofibroblast differentiation. Circulation Research 2008; 102: 319-327
    CrossrefPubMedGoogle Scholar
  • 56 Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporosis International 2007; 18: 427-444
    CrossrefPubMedGoogle Scholar
  • 57 Campos Pastor M, Lopez-Ibarra P, Escobar-Jimenez F. et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study. Osteoporosis International 2000; 11: 455-459
    CrossrefPubMedGoogle Scholar
  • 58 Danielson KK, Elliott ME, LeCaire T. et al. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporosis International 2009; 20: 923-933
    CrossrefPubMedGoogle Scholar
  • 59 Ponder SW, Brouhard BH, Travis LB. Hyperphosphaturia and hypermagnesuria in children with IDDM. Diabetes Care 1990; 13: 437-441
    CrossrefPubMedGoogle Scholar